# SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer

Source: https://onco.cc/trials/nct05020769/  
OnCo record `nct05020769` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial testing SI-B001 in non-small-cell lung cancer, active and no longer recruiting.

## Summary

SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer is a phase 2/3 interventional study registered as NCT05020769, led by Sichuan Baili Pharmaceutical, and active but no longer recruiting on the registry. Official title: A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in Combination With Osimertinib Mesylate Tablets in the Treatment of Recurrent and Metastatic Non- Small Cell Lung Cancer. Planned enrolment is 14 participants (actual). The study started in 2022-01-06 and primary completion is expected in 2025-12. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT05020769
- Phase: 2/3
- Setting: A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in Combination With Osimertinib Mesylate Tablets in the Treatment of Recurrent and Metastatic Non- Small Cell Lung Cancer
- Sponsor: Sichuan Baili Pharmaceutical
- Enrolled: 14

## Sources

- ClinicalTrials.gov NCT05020769: https://clinicaltrials.gov/study/NCT05020769

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [SI-B001](https://onco.cc/drugs/si-b001/)
- companies: [SystImmune / Sichuan Biokin](https://onco.cc/companies/systimmune/)

---
JSON: https://onco.cc/api/v1/entities/nct05020769.json